CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-05 | Dunn Judith Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2026-04-29 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Pre-Funded Warrants (Right to Buy) | +2,106,000 | $9.50 | $20.0M | 22,546,000 |
| 2026-02-26 | Thomas Stephen Basil Director | Sale 10b5-1 | −16,313 | $7.01 | $114K | 154,657 |
| 2026-02-25 | Thomas Stephen Basil Director | Sale 10b5-1 | −33,687 | $7.00 | $236K | 170,970 |
| 2026-02-13 | Thomas Stephen Basil Director | Sale 10b5-1 | −10,000 | $5.81 | $58K | 204,657 |
| 2026-02-12 | Thomas Stephen Basil Director | Sale 10b5-1 | −90,000 | $5.23 | $471K | 214,657 |
| 2026-01-06 | Brennan Aoife President and CEO | Grant or award · Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2026-01-06 | Wilson Perrin Megan Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2026-01-06 | ALTSCHULLER Susan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +142,500 | 142,500 | ||
| 2026-01-06 | Driscoll Cindy Senior Vice President, Finance | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-01-05 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +7,111 | $3.50 | $25K | 3,403,429 |
| 2025-12-12 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +101,462 | $2.86 | $290K | 3,396,318 |
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. Director | Returned to the company | −20,440,000 | 3,081,757 | ||
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +213,099 | $2.18 | $465K | 3,294,856 |
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Pre-Funded Warrants (Right to Buy) | +20,440,000 | 20,440,000 | ||
| 2025-10-01 | ALTSCHULLER Susan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2025-08-07 | Thomas Stephen Basil Director | Grant or award | +100,375 | 304,657 | ||
| 2025-06-30 | Brennan Aoife President and CEO | Sale 10b5-1 | −20,618 | $1.22 | $25K | 48,132 |
| 2025-06-27 | Brennan Aoife President and CEO | Option exercise 10b5-1 | +68,750 | 68,750 | ||
| 2025-06-27 | Brennan Aoife President and CEO | Option exercise · Restricted Stock Units 10b5-1 | −68,750 | 206,250 |
Page 2 of 9 · 166 trades